Skip to main content

Strattera (Atomoxetine): Non-Stimulant ADHD Medication Guide

|April 11, 2026|6 min read
Strattera (Atomoxetine): Non-Stimulant ADHD Medication Guide

Atomoxetine (Strattera) is an ADHD medicine that the UK prescribing information describes as not a psychostimulant (emc, Atomoxetine Glenmark 60 mg hard capsules, summary of product characteristics, date of revision of the text 28/10/2024, section 5.1, read 7 November 2026). This guide sets out what the UK and US prescribing documents and the NICE ADHD guideline say about how it works, when it is offered, its dosing, reviews and side effects.

How Atomoxetine Differs From Stimulants

Mechanism: What the prescribing documents say, all read on 7 November 2026:

  • Atomoxetine, UK: atomoxetine is a highly selective and potent inhibitor of the pre-synaptic noradrenaline transporter, its presumed mechanism of action, without directly affecting the serotonin or dopamine transporters; it is not a psychostimulant and is not an amphetamine derivative (emc, Atomoxetine Glenmark 60 mg hard capsules, summary of product characteristics, date of revision of the text 28/10/2024, section 5.1).
  • Atomoxetine, US: the precise mechanism by which Strattera produces its therapeutic effects in ADHD is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter (Strattera, FDA label on DailyMed, revised 06/2026, section 12.1).
  • Lisdexamfetamine (Elvanse), UK: amfetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity; the mode of therapeutic action of amfetamine in ADHD is not fully established, however it is thought to be due to its ability to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space (emc, Elvanse 30mg Hard Capsules, summary of product characteristics, date of revision of the text 02/10/2026, section 5.1).

Profile: What the prescribing documents say about abuse and control, both read on 7 November 2026:

  • UK: in a randomised, double-blind, placebo-controlled, abuse-potential study in adults comparing effects of atomoxetine and placebo, atomoxetine was not associated with a pattern of response that suggested stimulant or euphoriant properties (emc, Atomoxetine Glenmark 60 mg hard capsules, summary of product characteristics, date of revision of the text 28/10/2024, section 5.1).
  • US: Strattera contains atomoxetine, which is not a controlled substance (section 9.1); in a randomized, double-blind, placebo-controlled, abuse-potential study in adults that compared effects of Strattera and placebo, Strattera was not associated with stimulant or euphoriant properties (section 9.2) (Strattera, FDA label on DailyMed, revised 06/2026).

Effectiveness: Whether atomoxetine suits you is for your prescriber to judge. What the two documents say, both read on 7 November 2026:

  • UK prescribing information: in each of six placebo-controlled trials in adults, atomoxetine was statistically significantly superior to placebo in reducing ADHD signs and symptoms. In a 6 week paediatric study that tested the non-inferiority of atomoxetine to a standard extended-release methylphenidate comparator, the comparator was shown to be associated with superior response rates compared to atomoxetine, and the study excluded patients who were stimulant nonresponders (emc, Atomoxetine Glenmark 60 mg hard capsules, summary of product characteristics, date of revision of the text 28/10/2024, section 5.1).
  • NICE guideline NG87: offer atomoxetine to adults if they cannot tolerate lisdexamfetamine or methylphenidate or their symptoms have not responded to separate 6-week trials of lisdexamfetamine and methylphenidate, having considered alternative preparations and adequate doses (recommendation 1.7.15); offer the same medication choices to people with ADHD and anxiety disorder, tic disorder or autism spectrum disorder as other people with ADHD (recommendation 1.7.18) (published 14 March 2018, last updated 13 September 2019).

When to Review

Your prescriber sets when to review how atomoxetine is working and how long to wait before deciding whether it suits you; ask at the start. Do not stop atomoxetine or change the dose on your own. The dosing section below gives the starting dose and the minimum time at that dose that the UK prescribing information names.

Who Is Atomoxetine For?

Your prescriber decides whether atomoxetine is offered to you. The Effectiveness list above gives the NICE recommendation on when atomoxetine is offered to adults. What the UK prescribing information says (emc, Atomoxetine Glenmark 60 mg hard capsules, summary of product characteristics, date of revision of the text 28/10/2024, read 7 November 2026):

  • Should not be used (section 4.3): in combination with monoamine oxidase inhibitors (MAOI) or within a minimum of 2 weeks after discontinuing therapy with MAOI; in patients with narrow angle glaucoma; in patients with severe cardiovascular or cerebrovascular disorders; in patients with pheochromocytoma or a history of pheochromocytoma.
  • Liver (section 4.2): for patients with moderate hepatic insufficiency (Child-Pugh Class B) and for patients with severe hepatic insufficiency (Child-Pugh Class C), the initial and target doses should be reduced; the document gives the reduction for each class.
  • Mood and anxiety (section 4.4): patients who are being treated for ADHD should be carefully monitored for the appearance or worsening of suicide related behaviour, and patients who are being treated for ADHD with atomoxetine should be monitored for the appearance or worsening of anxiety symptoms, depressed mood and depression or tics.

Dosing

Your prescriber sets the dose and the schedule; follow the leaflet that comes with your medicine. For adults, the UK prescribing information for atomoxetine says to start at a total daily dose of 40 mg and to keep the initial dose for a minimum of 7 days before raising it according to clinical response and tolerability. It gives a recommended maintenance daily dose of 80 mg to 100 mg and a maximum recommended total daily dose of 100 mg (emc, Atomoxetine Glenmark 60 mg hard capsules, summary of product characteristics, date of revision of the text 28/10/2024, read 7 November 2026). For children and adolescents up to 70 kg body weight, the same document doses by body weight. The same document says atomoxetine can be administered as a single daily dose in the morning, and that patients who do not achieve a satisfactory clinical response (tolerability [e.g., nausea or somnolence] or efficacy) on a single daily dose might benefit from taking it as twice daily evenly divided doses in the morning and late afternoon or early evening (section 4.2, read 7 November 2026).

The UK prescribing information says atomoxetine can be administered with or without food (emc, Atomoxetine Glenmark 60 mg hard capsules, summary of product characteristics, date of revision of the text 28/10/2024, sections 4.2 and 5.2, read 7 November 2026). Follow the schedule your prescriber has set.

Side Effects

What the UK prescribing information says about the side effects of atomoxetine (emc, Atomoxetine Glenmark 60 mg hard capsules, summary of product characteristics, date of revision of the text 28/10/2024, section 4.8, read 8 November 2026):

  • In the table of adverse reactions for adults, nausea, dry mouth and decreased appetite are listed as Very common (≥1/10), and fatigue, dizziness and constipation as Common (≥1/100 to <1/10).
  • Nausea (26.7%) is among the most common adverse events reported in adult ADHD clinical trials; the majority of these events were mild or moderate in severity, and the events most frequently reported as severe were nausea, insomnia, fatigue and headache.

Other reactions that the same adults table lists, by the frequency category it prints (emc, Atomoxetine Glenmark 60 mg hard capsules, summary of product characteristics, date of revision of the text 28/10/2024, section 4.8, read 7 November 2026):

  • Very common (≥1/10): insomnia, headache, blood pressure increased, heart rate increased.
  • Common (≥1/100 to <1/10): urinary retention, erectile dysfunction, ejaculation disorder, libido decreased, irritability, anxiety, depression and depressed mood.
  • Uncommon (≥1/1,000 to <1/100): ejaculation failure, orgasm abnormal, suicide-related events, emotional lability, allergic reactions.
  • Rare (≥1/10,000 to <1/1,000): abnormal/increased liver function tests, jaundice, hepatitis, liver injury, acute hepatic failure, blood bilirubin increased.

Section 4.4 of the same document says that, very rarely, spontaneous reports of liver injury, manifested by elevated hepatic enzymes and bilirubin with jaundice, have been reported, and also very rarely severe liver injury, including acute liver failure; atomoxetine should be discontinued in patients with jaundice or laboratory evidence of liver injury, and should not be restarted (emc, Atomoxetine Glenmark 60 mg hard capsules, summary of product characteristics, date of revision of the text 28/10/2024, read 7 November 2026).

If nausea persists, tell your clinician; the dosing section above gives what the UK prescribing information says about splitting the daily dose when tolerability is a problem, and your clinician decides whether to change the dose schedule, the dose or the medicine. Tell your clinician if fatigue or any other side effect troubles you.

Monitoring and Safety

The UK prescribing information says to measure and record heart rate and blood pressure before treatment is started and, during treatment, after each adjustment of dose and then at least every 6 months (emc, Atomoxetine Glenmark 60 mg hard capsules, summary of product characteristics, date of revision of the text 28/10/2024, read 7 November 2026). The US label says that liver enzyme and function tests should be obtained upon the first symptom or sign of liver dysfunction, for example pruritus, dark urine, jaundice, right upper quadrant tenderness, or unexplained "flu like" symptoms (Strattera, FDA label on DailyMed, revised 06/2026, section 5.2, read 7 November 2026). Ask your prescriber which checks you need.

Mood: section 4.4 of the UK prescribing information says that patients who are being treated for ADHD should be carefully monitored for the appearance or worsening of suicide related behaviour, and that patients who are being treated for ADHD with atomoxetine should be monitored for the appearance or worsening of anxiety symptoms, depressed mood and depression or tics (emc, Atomoxetine Glenmark 60 mg hard capsules, summary of product characteristics, date of revision of the text 28/10/2024, read 7 November 2026).

Sexual function: NICE guideline NG87 says to monitor young people and adults with ADHD for sexual dysfunction (that is, erectile and ejaculatory dysfunction) as potential adverse effects of atomoxetine (recommendation 1.8.15, published 14 March 2018, last updated 13 September 2019, read 7 November 2026). The US label says that Strattera impaired sexual function in some patients, and that health care providers should routinely inquire about sexual dysfunction (Strattera, FDA label on DailyMed, revised 06/2026, section 6.1, read 7 November 2026). Tell your clinician if this becomes a problem; whether to change the dose or the medicine is for your prescriber to decide.

Appetite and weight: in the table of adverse reactions for adults, the UK prescribing information lists appetite decreased as Very common (≥1/10) and weight decreased as Common (≥1/100 to <1/10), and it lists appetite decreased among the most common adverse events reported in adult ADHD clinical trials (appetite decreased, 14.9%) (emc, Atomoxetine Glenmark 60 mg hard capsules, summary of product characteristics, date of revision of the text 28/10/2024, section 4.8, read 8 November 2026). NICE guideline NG87 says to measure weight every 6 months in adults taking medication for ADHD, and gives other intervals for children and young people (recommendation 1.8.5, published 14 March 2018, last updated 13 September 2019, read 8 November 2026). Tell your clinician if your appetite or weight changes.

Practical Tips

NICE guideline NG87 says to encourage people with ADHD to use visual reminders to take medication regularly (for example, apps, alarms, clocks, pill dispensers, or notes on calendars or fridges) (recommendation 1.9.4, published 14 March 2018, last updated 13 September 2019, read 7 November 2026).

What the UK prescribing information says (emc, Atomoxetine Glenmark 60 mg hard capsules, summary of product characteristics, date of revision of the text 28/10/2024, sections 4.7 and 4.8, read 7 November 2026):

  • Nausea: if nausea is strong, ask your prescriber about the dose schedule (the dosing section above gives what the document says).
  • Driving: atomoxetine has a minor influence on the ability to drive and use machines, and has been associated with increased rates of fatigue, somnolence, and dizziness relative to placebo; patients should be advised to use caution when driving a car or operating hazardous machinery until they are reasonably certain that their performance is not affected by atomoxetine (section 4.7).
  • Constipation: listed as Common (≥1/100 to <1/10) in the adults table (section 4.8). Ask your pharmacist or prescriber what to do if it troubles you.

Ask your prescriber how long to give atomoxetine before deciding whether it is working, and do not stop it on your own. Ask your prescriber whether to keep a symptom diary of your focus and impulse control.

Disclaimer

This article is educational only and not medical advice. In the US, the Strattera prescribing information carries a boxed warning about suicidal thoughts and behaviors in pediatric patients 6 years of age and older, and says Strattera increased the risk of suicidal ideation in these patients in short-term studies (FDA label on DailyMed, revised 06/2026, read 7 November 2026). The FDA directed the manufacturer to add a boxed warning on suicidal thinking in children and adolescents in a public health advisory created on September 29, 2005 (archived copy of the FDA page at webarchive.library.unt.edu, captured 24 September 2008, read 7 November 2026). Do not start, stop, or adjust doses without clinician guidance. Discuss your mood history, liver health, and cardiovascular risk factors with your prescriber before treatment.

Further Reading and Assessment

Note how you feel before you start and at the reviews your prescriber sets. Take the Focus & Energy Check-In as a personal record to bring to those reviews; like every self-check on JobCannon it is for personal awareness only and cannot diagnose any condition.

References:

  • Michelson, D., et al. (2001). "Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study." Pediatrics, 108(5), E83.
  • Kratochvil, C. J., et al. (2002). "Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial." Journal of the American Academy of Child & Adolescent Psychiatry, 41(7), 776–784.
  • US Food and Drug Administration. (2005). "Public Health Advisory: Suicidal Thinking in Children and Adolescents Being Treated With Strattera (Atomoxetine)." Date created September 29, 2005. Archived copy (webarchive.library.unt.edu, captured 24 September 2008), read 7 November 2026.
  • US Food and Drug Administration. Strattera (atomoxetine) capsules, prescribing information (initial US approval 2002). DailyMed, label revised 06/2026, read 7 November 2026.

Ready when you are

Find your focus and attention pattern in 3 minutes.

24 questions. Full result with strengths and blind spots.